Accord BioPharma Announces Commercial Availability of Denosumab Biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu)

RegulatoryapprovedOSVYRTI®JUBEREQ®Positive

AI Analysis

Summary

Accord BioPharma announced commercial availability of two denosumab biosimilars, OSVYRTI® and JUBEREQ®, for treatment of bone health conditions. The approvals expand treatment access in the biosimilar market.

Outcome Details

Commercial availability announced for denosumab biosimilars

Importance:5/10

Sentiment:

0.60

biosimilardenosumabbone healthcommercial launchspecialty pharma

Related Companies

$DFPH $HIT

Read the original article

Published by PR Newswire Biotech on July 23, 2026 12:05 PM

Read Original